| 章伟玲,王微微,孙琰珺,等.尿微小RNA特征谱预测宫颈癌淋巴结转移[J].肿瘤学杂志,2025,31(11):930-937. |
| 尿微小RNA特征谱预测宫颈癌淋巴结转移 |
| Urinary MicroRNA Signature for Predicting Lymph Node Metastasis in Cervical Cancer |
| 投稿时间：2024-12-25 |
| DOI：10.11735/j.issn.1671-170X.2025.11.B002 |
|
 |
| 中文关键词: 宫颈肿瘤 淋巴结转移 尿液样本 微小RNA |
| 英文关键词:cervical neoplasms lymph node metastasis urine sample microRNA |
| 基金项目:江苏省卫生健康委面上项目（M2020010） |
|
| 摘要点击次数: 13 |
| 全文下载次数: 1 |
| 中文摘要: |
| 摘 要：［目的］ 筛选宫颈癌患者淋巴结转移（lymph node metastasis ，LNM）阳性相关的尿微小RNA（microRNA，miRNA），并评价其诊断价值。［方法］ 收集2017年1月至12月在南通市肿瘤医院诊治的宫颈癌患者术前尿液样本（发现集），包括12例LNM阳性患者和13例LNM阴性患者，使用GeneChip miRNA 3.0阵列鉴定尿液全基因组miRNA谱。收集2018年1月至2023年11月96例宫颈癌患者的尿液样本（验证集），采用逆转录实时定量聚合酶链式反应法检测尿miRNA表达，并使用受试者工作特征曲线和Logistic回归分析来确定与LNM阳性相关的miRNA，并构建预测模型。［结果］ 微阵列表达谱鉴定了33个差异表达的miRNA，进一步缩窄筛选标准（错误发现率＜0.05，倍数变化＜0.05或＞2.0），共鉴定8种miRNA差异表达：miR-7a-5p、miR-483-5p、miR-552和miR-92b-5p过表达；miR-375、miR-486-5p、miR-92a-3p和miR-195-3p低表达。经验证集验证，miR-483-5p（2.64 vs 1.78，P=0.008）、miR-552（2.63 vs 1.59，P=0.001）、miR-92b-5p（2.60 vs 1.85，P=0.019）在LNM阳性组中表达上调；miR-375（1.35 vs 2.19，P＜0.001）、miR-486-5p（1.57 vs 2.26，P=0.003）在LNM阳性组中表达下调。多因素分析显示尿miRNA（miR-483-5p、miR-552、miR-92b-5p、miR-375）与LNM阳性状态存在独立的相关关系（P＜0.05）。构建这4种miRNA组合模型，该模型正确地分类了78.57%（11/14）的LNM阳性样本和93.90%（77/82）的LNM阴性样本。［结论］ 一种包含miR-483-5p、miR-552、miR-92b-5p和miR-375的尿液 miRNA 特征有望成为预测宫颈癌淋巴结转移的无创生物标志物。 |
| 英文摘要: |
| Abstract：［Objective］ To identify urinary microRNA (miRNA) signatures associated with lymph node metastasis (LNM) in cervical cancer and assess their diagnostic potential. ［Methods］ Preope-rative urine samples were collected from cervical cancer patients who underwent radical hysterectomy and pelvic lymphadenectomy at Nantong Tumor Hospital between January and December 2017. A discovery set (12 positive LNM and 13 negative LNM patients) was analyzed using GeneChip miRNA 3.0 arrays to define genome-wide miRNA profiles. From January 2018 to November 2023， urine samples from 96 patients with cervical cancer were collected (validation set)， differentially expressed miRNAs were validated by real-time quantitative reverse transcription polymerase chain reaction. Receiver operating characteristic curves and Logistic regression analy-ses were employed to evaluate diagnostic performance and construct a predictive model. ［Results］ Microarray analysis identified 33 differentially expressed miRNAs. Applying stricter criteria (false discovery rate <0.05， fold change <0.05 or >2.0)， eight miRNAs were identified as differentially expressed： miR-7a-5p， miR-483-5p， miR-552 and miR-92b-5p were upregulated; miR-375， miR-486-5p， miR-92a-3p and miR-195-3p were downregulated. In the validation set， miR-483-5p (2.64 vs 1.78，P=0.008)， miR-552(2.63 vs 1.59，P=0.001)， and miR-92b-5p (2.60 vs 1.85，P=0.019) were significantly upregulated， whereas miR-375 (1.35 vs 2.19，P＜0.001) and miR-486-5p (1.57 vs 2.26，P=0.003) were downregulated in positive LNM patients (all P<0.05). Multivariate analysis confirmed that miR-483-5p， miR-552， miR-92b-5p， and miR-375 were independently associated with positive LNM status. A combination model based on these four miRNAs correctly classified 78.57% (11/14) of positive LNM and 93.90% (77/82) of negative LNM samples. ［Conclusion］ A urinary miRNA signature comprising miR-483-5p， miR-552， miR-92b-5p and miR-375 shows promise as a noninvasive biomarker for predicting LNM in cervical cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |